Global pharmaceutical company Merck (NYSE:MRK) in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with ...
TAIPEI (Taiwan News) — Germany-based Merck has opened a new semiconductor materials facility in Kaohsiung, a move analysts say will strengthen Taiwan’s back-end semiconductor supply chain, CTEE ...
AUSTIN, TX, UNITED STATES, August 4, 2025 /EINPresswire.com/ -- Electroninks, the leader in metal organic decomposition (MOD) inks for additive manufacturing and ...
Merck’s MRK PD-L1 inhibitor, Keytruda, approved for several types of cancers, alone accounts for around 46% of the company’s pharmaceutical sales. Keytruda has played an instrumental role in driving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback